Changchun High-Tech Industry's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, received approval from the Chinese drug administration to conduct clinical trials on the GenSci134 injection, according to a Shenzhen bourse disclosure on Saturday.
The pharmaceutical company's shares dropped less than 4% during the Monday's morning trade.
The drug is being developed as a treatment for growth hormone deficiency in both adults and children.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments